<div id="readability-page-1"><p>Zurcher Kantonalbank Zurich Cantonalbank lessened its stake in shares of  Dynavax Technologies Co. (NASDAQ:DVAX - Free Report) by 78.1% in the 3rd quarter, according to the company in its most recent filing with the Securities &amp; Exchange Commission. The fund owned 25,880 shares of the biopharmaceutical company's stock after selling 92,157 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank's holdings in Dynavax Technologies were worth $288,000 as of its most recent filing with the Securities &amp; Exchange Commission.</p><div><p><span></span><span>Get <strong>Dynavax Technologies</strong> alerts:</span></p></div><p>A number of other hedge funds and other institutional investors have also recently bought and sold shares of the stock. Renaissance Technologies LLC lifted its stake in  Dynavax Technologies by 2.2% in the 2nd quarter. Renaissance Technologies LLC now owns 2,478,178 shares of the biopharmaceutical company's stock worth $27,830,000 after purchasing an additional 53,600 shares in the last quarter.  Great Point Partners LLC lifted its position in  Dynavax Technologies by 87.7% during the second quarter. Great Point Partners LLC now owns 2,374,000 shares of the biopharmaceutical company's stock worth $26,660,000 after buying an additional 1,109,080 shares in the last quarter.  Millennium Management LLC purchased a new stake in  Dynavax Technologies in the 2nd quarter valued at $17,615,000.  Mizuho Markets Americas LLC increased its stake in shares of  Dynavax Technologies by 17.4% in the 3rd quarter. Mizuho Markets Americas LLC now owns 1,379,582 shares of the biopharmaceutical company's stock worth $15,369,000 after acquiring an additional 204,475 shares during the last quarter.  Finally, Bank of Montreal Can raised its holdings in shares of  Dynavax Technologies by 8.3% during the 3rd quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company's stock worth $11,848,000 after acquiring an additional 82,449 shares during the period. 96.96% of the stock is owned by hedge funds and other institutional investors. </p><h2>Dynavax Technologies Price Performance</h2><p>Dynavax Technologies stock opened at $12.85 on Monday. The company has a quick ratio of 12.34, a current ratio of 13.23 and a debt-to-equity ratio of 0.33. Dynavax Technologies Co. has a 52-week low of $9.74 and a 52-week high of $15.01. The firm has a market cap of $1.69 billion, a PE ratio of 98.85 and a beta of 1.33. The company's 50 day moving average is $11.85 and its two-hundred day moving average is $11.44. </p><h2>Wall Street Analysts Forecast Growth</h2><p>Separately, HC Wainwright  reissued a &#34;buy&#34; rating and issued a $29.00 price target on shares of Dynavax Technologies in a research note on Friday, November 8th.</p><p><b>View Our Latest Stock Analysis on Dynavax Technologies</b></p><h2>Dynavax Technologies Company Profile</h2> (Free Report)<p>Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.</p><h2>Further Reading</h2><ul><li>Five stocks we like better than Dynavax Technologies</li><li>Dividend Capture Strategy: What You Need to Know</li><li>Guidewire Software Provides Long-Awaited Buying Opportunity</li><li>What is the Euro STOXX 50 Index?</li><li>What’s Behind These 3 Recent Analyst Stock Upgrades?</li><li>The How And Why of Investing in Oil Stocks</li><li>Fast-Growing Companies That Are Still Undervalued</li></ul><p><strong>Want to see what other hedge funds are holding DVAX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dynavax Technologies Co. (NASDAQ:DVAX - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFZBWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9RFZBWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><p>→ Musk’s new company could top a trillion? <span><span>(From Paradigm Press)</span> <span>(Ad)</span></span><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDY3Mg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" height="1" width="1" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/TriggeredCampaignPixel.ashx/query-UGxhY2VtZW50PU5hdGl2ZURpc3BsYXkmU291cmNlPU5hdGl2ZURpc3BsYXkmVHJpZ2dlcmVkQ2FtcGFpZ25JRD0xMDY3Mg"/></p><h2>Should you invest $1,000 in Dynavax Technologies right now?</h2><p>Before you consider Dynavax Technologies, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Dynavax Technologies wasn't on the list.</p><p>While Dynavax Technologies currently has a &#34;Moderate Buy&#34; rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

DVAX

<p>Zurcher Kantonalbank Zurich Cantonalbank reduced its stake in Dynavax Technologies Co. (NASDAQ:DVAX) by 78.1% in Q3, now holding 25,880 shares after selling 92,157 shares. Other institutional investors, including Renaissance Technologies and Great Point Partners, have also adjusted their positions. Dynavax Technologies has a market cap of $1.69 billion and a PE ratio of 98.85. Analysts maintain a "buy" rating with a price target of $10.00. The company focuses on developing vaccines, including HEPLISAV-B for hepatitis B.</p>

Dynavax Technologies Co. (NASDAQ:DVAX) Shares Sold by Zurcher Kantonalbank Zurich Cantonalbank